
THIS IS LIFE SCIENCES

3-6 June 2019

B I O
2 0 1 9
U S A



Cymru
Wales

UPCOMING TRADE EVENTS

Florida International Medical Expo

26-28 July 2019

Miami

Medica

18-21 November 2019

Dusseldorf, Germany



UNDEB EWROPEAIDD
EUROPEAN UNION



Llywodraeth Cymru
Welsh Government

**Cronfa Datblygu
Rhanbarthol Ewrop
European Regional
Development Fund**

WG37755
© Crown copyright 2019

OGL

W E L S H
G O V E R N M E N T



Llywodraeth Cymru
Welsh Government

*Wales at BIO International
Convention 2019*

The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. Bringing together a wide spectrum of life science and application areas including drug discovery and genomics.

Our support to this delegation reflects the Welsh Governments commitment to the Life Sciences in Wales.

Come and talk to us

**Wales Pavilion:
Stand 3735**

Richard Harris
Head of Life Sciences Sector
richard.harris@gov.wales
Mob: +44 (0)7891 423 903

Contact us


Tel: +44 (0)3000 6 03000
tradeandinvest.wales

*Welsh Government Office,
United States of America*

Jonathan Walters
Deputy Head of North America
jonathan.walters@gov.wales
Tel: +1 202 588 6623

Efe Sokol
Senior Business Representative
efe.sokol@gov.wales
Tel: +1 212 745 0415

Kelly Taylor
Business Development Executive
kelly.taylor002@gov.wales



Infographic reproduced courtesy of Advances Wales.

L I F E S C I E N C E S I N W A L E S

Wales has a whole-system approach to health and social care, underpinned by a national digital infrastructure. It is a global leader in value-based healthcare and tracking outcomes and is home to some of the world's most progressive and exciting companies within the growing Life Sciences industry.

Wales is an ideal partner system for rapid adoption and evaluation of new medicines, technologies and services.

This year we've seen key projects emerge including:

- Through a partnership that brings together EU, Welsh Government and academic investment of £24m, the ACCELERATE Programme, led by the Life Sciences Hub Wales will focus on accelerating the exploitation of innovation and technology opportunities that meet needs across the health and social care system.
- The UK Dementia Research Institute at Cardiff is a £20m research centre aimed at finding effective treatments for dementia, with more than

70 global scientists and plans to grow to 100. The centre is one of six that make up the UK Dementia Research Institute (UK DRI) with a total £290m investment. It will build upon ground breaking scientific research strengths in dementia genetics; immunology; computational analytics; and neuroimaging to identify disease mechanisms and therapies. This will identify new targets for drug development, develop new approaches for delivering effective clinical trials and attract industry partnerships to develop new therapeutics and diagnostics.

The Life Sciences Sector includes around 370 companies, employing 12,000 people in well paid, high quality jobs across the country.

The Life Sciences sector is inherently collaborative, working across government and the wider public and private sector to deliver prosperity for all, combining our many strengths with the clear aim of putting the patients and people of Wales first.



The Welsh Government is committed to supporting the sector through a wide range of mechanisms, offering highly competitive programmes of business advice, finance and trade support as part of its Economic Action Plan.

Our vision for Life Sciences is to make Wales the place of choice for health, care and wellbeing innovation. We aim to support a higher value and more sustainable health and care system, and a more productive and competitive economy, offering high quality employment opportunities.

Life Sciences Hub Wales

Life Sciences Hub Wales (LSHW) Ltd is a Welsh Government subsidiary that supports a growing and prosperous Life Sciences sector in Wales. LSHW aims to accelerate the development

and adoption of innovative solutions for improved health and wellbeing for the people of Wales.

Whether your organisation is small with big ambitions or established and looking to achieve further growth, LSHW is here to provide access to advice, information and support to increase prosperity and growth.

To learn more about engagement with health and care services in Wales, whilst helping the NHS in Wales implement innovative solutions to their challenges and unmet needs, please contact:

+44(0)29 2046 7030
hello@lshubwales.com



Life Sciences Hub | Wales
Hwb Gwyddorau Bywyd | Cymru

T H I S I S W A L E S . T H I S I S C O N N E C T E D .

The world of business rarely stands still; the search for new opportunities, new ventures and new partnerships drives innovation across Wales. Whatever happens around us, Wales will continue to provide a strong, stable and secure environment for enterprise. We are always open to new ideas and driven by an innovative, entrepreneurial spirit; not just dreaming big, but making it happen.

There are many reasons why doing business in Wales gives you a distinct advantage – from skills to strategic partnerships, and a tailored approach to financial support. We provide a personal response to business with clear lines of communication with Government. And the links between business and academic institutions grow stronger every year.

Wales is a country that forms part of the UK and has a population of three million people. Since 1999, the country has had its own devolved Government, with control over its own economic development and spending. Welcoming businesses for many years, we have been helping them to thrive, grow and realise their potential. Companies that locate here have the advantage of easy access to the UK market, with its population of 65 million.

Wales continues to develop close relationships with international partners, in the United States, Europe and further afield. We have a great story to tell, of an agile and innovative nation with a truly global outlook.

B I O C A T A L Y S T S L T D



Company Background

Biocatalysts Ltd, winners of the Queen's Award for Innovation 2019, is a global biotechnology company that has been producing speciality enzymes for a variety of industries for over 35 years. The company has been built on an ethos of actively working with customers to develop enzyme-based solutions that meet customer challenges. Biocatalysts prides itself on providing good technical knowledge and superb customer service and does this by using the best technologies available and keeping abreast of the newest advancements that impact the biotech industry.

Biocatalysts offer both off-the-shelf enzyme products and an awarding winning customised enzyme discovery, development and manufacturing service. The latter is where the company excel, identifying novel enzymes in hours rather than days via its bespoke software system, MetXtra™. Selected enzymes can then be developed and scaled up within

months instead of a few years, meaning that new enzymes can be produced in timeframes that can have a critical impact on the processes and products companies develop.

Biocatalysts is a company never to rest on its laurels and are continually looking for ways to improve its offering. Having made its biggest investment to date; a £6 million extension, with a new 10m³ fermenter and downstream processing to increase the company's fermentation capacity more than 10-fold and new mini fermenters that will reduce development time even further.

For more information please visit the website www.biocatalysts.com or make contact via enquiries@biocats.com.

Contact

Andrew Ellis
Technical and compliance Director
andrewe@biocats.com

C A T S C I



Company Background

An award-winning and scientifically-unbiased process research and development CRO that provides perfect-for-purpose chemistry services and non-GMP material supply to emerging, mid-sized and large pharma. We proudly serve customers across the globe from lead optimisation through to product launch and life-cycle management.

Our large pharma pedigree and extensive experience working on small molecule drug discovery and development projects mean that we can expedite your candidate selection, route design, process scale-up and optimisation, whilst ensuring seamless tech transfer for GMP manufacturing.

Favouring a consultative approach, we take the time to understand your project objectives to design and deliver tailored solutions to match your specific demands.

Non-GMP material supply from milligrams to kilograms is conveniently carried out in our laboratory, whilst for larger quantities and/or GMP manufacture, we are able to work with our trusted partners or your preferred supplier.

To explore how we can take your projects to the next step, please contact us at technical_enquiries@catsci.com or visit our website catsci.com.

Contact

Jenny Wallis, PhD
Manager – Business Development
jenny.wallis@catsci.com

GENOMICS PARTNERSHIP WALES



Company Background

Wales continues to prove itself as an ideal location for companies in the life sciences sector to establish themselves and flourish. The sector draws together business, academia and healthcare stakeholders to harness the potential to drive transformational change across the Welsh health and care system, improving patient outcomes and creating value for our economy.

Wales is home to world leading academics and researchers who lead ground breaking work in cell and gene therapies, genetics and genomics, in vitro diagnostics as well as medical devices. We also have a strong record of attracting some of the most exciting and progressive companies involved in the growing international stage for precision medicine.

The Welsh Government has recently published its vision and bold ambitions for precision medicine in Wales. It is supported by national programmes for genomics, diagnostics and

advanced therapeutics that together will create a sustainable, internationally competitive environment for precision medicine.

All are underpinned by the recognition of the need to exploit the opportunities that will emerge from the vast amounts of patient data that will be collected and the application of deep learning and artificial intelligence techniques to improve decision making.

Precision medicine continues to enjoy significant support through nationally lead initiatives like the National Imaging Academy and the Rutherford Cancer Centre which will provide proton beam therapy for some adult cancer cases. Other proposals have seen recent investment in Illumina's NovaSeq 6000 system, as well as the development of a strategic approach for investment in positron emission tomography.

Genomics Partnership Wales, together with the other national programmes, provides the strong

platform to seek out strategic partnerships with industry and academia that can strengthen precision medicine research and services in Wales and deliver the biggest impact for patients whilst driving ongoing improvement, research and innovation in healthcare practice.

The experience from our collaborative working with industry and academic partners in Wales and the offer of meaningful engagement with patients and the public will help us to strengthen our national and international position in precision medicine.

Contact

Mark Briggs
Head of Cell and Gene Therapy
mark.briggs@wales.nhs.uk

HEALTH CARE RESEARCH WALES



Company Background

Health and Care Research Wales, is part of NHS Wales and is funded by Welsh Government. Our mission is to support and increase capacity in health and social care research within NHS Wales. Our broad research infrastructure and expert teams focus on Wales' current and emerging areas such as cancer, diabetes, respiratory, cardiology, lifestyle related disease and haematology.

The Health and Care Research Wales Support and Delivery Centre provides centralised support for the health and social care research community in Wales.

We work closely with national and international stakeholders from, industry, academia and the health and social care sector.

The industry team provides a range of services which are in place to help increase commercial research in NHS Wales:

- Signposting for companies and individuals wishing to discuss commercial research in Wales.
- All Wales Feasibility coordination service; site identification and site intelligence. All services are coordinated by the industry team and are accessible by emailing industry-research@wales.nhs.uk
- Early feedback service which links directly with key opinion leaders and NHS consultants from across 30 speciality areas.
- Access to NHS Consultants and patient populations.
- Contracts advice & support which is provided by our experienced contract manager and contract officer. This service is accessible by emailing researchcontracts@wales.nhs.uk

- Study set-up oversight, which aims to improve start-up of studies in Wales and exists to support companies experiencing set-up delays in Welsh sites.
- Coordinated oversight of commercial research delivery which includes a trouble shooting service which is responsive to the needs of industry.

Contact

Matthew Harris
Executive Team – Cluster Lead
matthew.harris@wales.nhs.uk

M E D I W A L E S



MediWales

Company Background

MediWales is the life science network for Wales and we provide support and business opportunities, whilst promoting collaboration within the life science sector. With over 200 members, our network is made up of biotechnology, pharmaceutical services and medical technology companies.

Our membership includes NHS health boards and universities.

We represent a thriving Life Sciences sector in Wales and provide support and creating business opportunities MediWales for our members. We also deliver a successful event programme including a number of conferences.

MediWales publishes a number of magazines including Life Science Industry magazine the most widely distributed sector publication in the UK. This year the Life Science Industry has launched with a hybrid digital/ print format. The aim to extend its international reach and customer base.

We will be working to increase profile of Life Science Industry magazine through distribution off UK pavilions, and one to one meetings with potential partners and sponsors.

Contact

Debbie Laubach
MediWales Operations Manager
info@mediwales.com

P C I P H A R M A S E R V I C E S



Company Background

PCI Pharma Services is an integrated full service provider, a proven and trusted partner to leading companies in the global healthcare industry. We offer unparalleled expertise and experience in taking compounds from the earliest stages of development through to successful commercialization, delivering speed-to-market and commercial success for our customers.

Our core services support each stage of the product lifecycle, including drug development, clinical trial supply, commercial launch and ongoing commercial supply. We partner with clients in providing innovative technologies, flexible solutions, and an integrated supply network supporting lifesaving medicines destined to over 100 countries around the world.

We support clients with a dedication to providing the industry's leading experience, exemplified in our operational flexibility, delivery, and commitment to safety, supported by industry leading technologies and an exemplary quality and regulatory record. This has allowed us to be the partner of choice for leading pharmaceutical companies around the world, operating as a seamless extension of their business.

Contact

Paul Viggers MSc
Director, Clinical Business
Development
+44 (0)1656 750 550
sales@pciservices.com

QUAY PHARMACEUTICALS LIMITED



Company Background

Quay Pharmaceuticals is experienced in providing a comprehensive out-sourcing service for formulation and analytical development with subsequent clinical trials and commercial manufacturing for pharmaceutical and biotechnology companies world-wide.

Working as a dedicated, pro-active part of your team we apply strong project management and technical expertise to take products quickly and cost effectively from late stage pre clinical through to the end of phase III clinical trials and Commercial Manufacturing.

Quay Pharma has vast expertise in dosage form design and development and with Prof Mike Rubinstein, Prof John Collett (CSO) and Prof Larry Gifford Quay Pharma has built a reputation for specialising in the formulation of API's that exhibit poor solubility and bio-availability and those which require modified or controlled release. This has resulted in many

Quay Pharma clients successfully licensing products on to large, global pharmaceutical companies.

From MHRA and FDA licensed inspected facilities the company provides;

- pre-clinical to commercial formulation development
- novel drug delivery system design
- analytical – transfer or method development and validation
- live biotherapeutic drug delivery'
- ICH stability testing
- clinical trial manufacture in class 100,000 (ISO 8) environment
 - conventional, coated and controlled release tablets and capsules
 - powder, liquid/semi-solid fill capsules
 - liquid/semi solid formulations (e.g. nasal and oral solutions, creams)
 - pellets/spheroids and extrudates
 - medical devices

- commercial manufacturing
- packing and labelling
- full QC testing services
- QP certification and importation of investigational medicinal products from outside the EU.
- CMC’s and regulatory document support for product registration

Quay Pharma holds a Manufacturing Authorisation from the MHRA for the manufacture and testing of investigational medicinal products (IMP’s), as specified by the EU Clinical Trials Directive (2001/20/EC) and also possesses a “Specials” licence.

Contact

Michael Kruidenier
Head of Business Development
+44 (0)1244 837 004
m.kruidenier@quaypharma.com
www.quaypharma.com

SWANSEA UNIVERSITY MEDICAL SCHOOL



Company Background

Swansea University Medical School is located in South West Wales in the United Kingdom.

The School educates and trains the next generation of doctors, life scientists, health professionals, innovators, educators, researchers and leaders. Educational courses build on the Schools excellent research which is ranked 2nd in the UK.

The School collaborates with the National Health Service, business and the third sector in a spirit of open innovation and has established itself as a world-class place to learn, research, innovate, collaborate and lead. This unique model has huge potential for delivering a sustainable health and life science knowledge economy. The community of likeminded clinicians, researchers and entrepreneurs collaborate to solve clinical challenges, taking research ideas from conception to commercialisation.

The Schools Enterprise and Innovation arm offers access to laboratories, an imaging suite and a clinical research facility.

The School offers expertise in biomedical research, public population health, informatics, tele-health, health services research, nano-technology and much more.

Contact

Prof. Steve Conlan

Head of Enterprise and Innovation
r.s.conlan@swansea.ac.uk

N O T E S



+44 (0) 3000 6 03000
tradeandinvest.wales